Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Mayo Clinic
University of Washington
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
National Cancer Institute (NCI)